カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

精神薬＆神経薬の世界市場2022：抗うつ薬、抗不安薬、抗精神病薬、気分安定薬、覚醒剤、その他

◆英語タイトル：Global Psychiatric and Nervous Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
	◆商品コード：GIR22NO19579 ◆発行会社（リサーチ会社）：GlobalInfoResearch ◆発行日：2022年11月（※2025年版があります。お問い合わせください。） ◆ページ数：111 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（注文後2-3日） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,480 ⇒換算￥528,960	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,220 ⇒換算￥793,440	見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）	USD6,960 ⇒換算￥1,057,920	見積依頼/購入/質問フォーム

★GlobalInfoResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

精神薬＆神経薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の精神薬＆神経薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

精神薬＆神経薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・抗うつ薬、抗不安薬、抗精神病薬、気分安定薬、覚醒剤、その他

用途別セグメントは次のように区分されます。
・病院調剤薬局、小売調剤薬局、オンライン調剤薬局

世界の精神薬＆神経薬市場の主要な市場プレーヤーは以下のとおりです。
・Pfizer、Ely Lilly、Actavis、Mylan、Randox、Intellipharmaceutics、Astrazeneca、Lundbeck、Allergan、GSK、Otsuka Pharmaceutical、Takeda、NHU Group、Shionogi、APOTEX、Chengdu Kanghong Pharmaceutical、HUAHAI、Zhejiang Jianfeng、Beijing Winsunny Pharmaceutical

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、精神薬＆神経薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な精神薬＆神経薬メーカーの企業概要、2019年～2022年までの精神薬＆神経薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な精神薬＆神経薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別精神薬＆神経薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの精神薬＆神経薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での精神薬＆神経薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および精神薬＆神経薬の産業チェーンを掲載しています。
・第13、14、15章では、精神薬＆神経薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 精神薬＆神経薬の概要
- 種類別分析（2017年vs2021年vs2028年）：抗うつ薬、抗不安薬、抗精神病薬、気分安定薬、覚醒剤、その他
- 用途別分析（2017年vs2021年vs2028年）：病院調剤薬局、小売調剤薬局、オンライン調剤薬局
- 世界の精神薬＆神経薬市場規模・予測
- 世界の精神薬＆神経薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Pfizer、Ely Lilly、Actavis、Mylan、Randox、Intellipharmaceutics、Astrazeneca、Lundbeck、Allergan、GSK、Otsuka Pharmaceutical、Takeda、NHU Group、Shionogi、APOTEX、Chengdu Kanghong Pharmaceutical、HUAHAI、Zhejiang Jianfeng、Beijing Winsunny Pharmaceutical
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：抗うつ薬、抗不安薬、抗精神病薬、気分安定薬、覚醒剤、その他
・用途別分析2017年-2028年：病院調剤薬局、小売調剤薬局、オンライン調剤薬局
・精神薬＆神経薬の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・精神薬＆神経薬のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・精神薬＆神経薬のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・精神薬＆神経薬の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・精神薬＆神経薬の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Psychiatric and Nervous Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Psychiatric and Nervous Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital Pharmacies accounting for % of the Psychiatric and Nervous Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Antidepressants segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Psychiatric and Nervous Drugs include Pfizer, Ely Lilly, Actavis, Mylan, and Randox, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Psychiatric and Nervous Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Antidepressants
Anti-anxiety
Antipsychotic
Mood Stabilizing
Stimulant Medications
Others
Market segment by Application can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The key market players for global Psychiatric and Nervous Drugs market are listed below:
Pfizer
Ely Lilly
Actavis
Mylan
Randox
Intellipharmaceutics
Astrazeneca
Lundbeck
Allergan
GSK
Otsuka Pharmaceutical
Takeda
NHU Group
Shionogi
APOTEX
Chengdu Kanghong Pharmaceutical
HUAHAI
Zhejiang Jianfeng
Beijing Winsunny Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Psychiatric and Nervous Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Psychiatric and Nervous Drugs, with price, sales, revenue and global market share of Psychiatric and Nervous Drugs from 2019 to 2022.
Chapter 3, the Psychiatric and Nervous Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Psychiatric and Nervous Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Psychiatric and Nervous Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Psychiatric and Nervous Drugs.
Chapter 13, 14, and 15, to describe Psychiatric and Nervous Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

❖ レポートの目次 ❖

1 Market Overview
1.1 Psychiatric and Nervous Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Psychiatric and Nervous Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Antidepressants
1.2.3 Anti-anxiety
1.2.4 Antipsychotic
1.2.5 Mood Stabilizing
1.2.6 Stimulant Medications
1.2.7 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Psychiatric and Nervous Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Psychiatric and Nervous Drugs Market Size & Forecast
1.4.1 Global Psychiatric and Nervous Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Psychiatric and Nervous Drugs Sales in Volume (2017-2028)
1.4.3 Global Psychiatric and Nervous Drugs Price (2017-2028)
1.5 Global Psychiatric and Nervous Drugs Production Capacity Analysis
1.5.1 Global Psychiatric and Nervous Drugs Total Production Capacity (2017-2028)
1.5.2 Global Psychiatric and Nervous Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Psychiatric and Nervous Drugs Market Drivers
1.6.2 Psychiatric and Nervous Drugs Market Restraints
1.6.3 Psychiatric and Nervous Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Psychiatric and Nervous Drugs Product and Services
2.1.4 Pfizer Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Ely Lilly
2.2.1 Ely Lilly Details
2.2.2 Ely Lilly Major Business
2.2.3 Ely Lilly Psychiatric and Nervous Drugs Product and Services
2.2.4 Ely Lilly Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Actavis
2.3.1 Actavis Details
2.3.2 Actavis Major Business
2.3.3 Actavis Psychiatric and Nervous Drugs Product and Services
2.3.4 Actavis Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Mylan
2.4.1 Mylan Details
2.4.2 Mylan Major Business
2.4.3 Mylan Psychiatric and Nervous Drugs Product and Services
2.4.4 Mylan Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Randox
2.5.1 Randox Details
2.5.2 Randox Major Business
2.5.3 Randox Psychiatric and Nervous Drugs Product and Services
2.5.4 Randox Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Intellipharmaceutics
2.6.1 Intellipharmaceutics Details
2.6.2 Intellipharmaceutics Major Business
2.6.3 Intellipharmaceutics Psychiatric and Nervous Drugs Product and Services
2.6.4 Intellipharmaceutics Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Astrazeneca
2.7.1 Astrazeneca Details
2.7.2 Astrazeneca Major Business
2.7.3 Astrazeneca Psychiatric and Nervous Drugs Product and Services
2.7.4 Astrazeneca Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Lundbeck
2.8.1 Lundbeck Details
2.8.2 Lundbeck Major Business
2.8.3 Lundbeck Psychiatric and Nervous Drugs Product and Services
2.8.4 Lundbeck Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Allergan
2.9.1 Allergan Details
2.9.2 Allergan Major Business
2.9.3 Allergan Psychiatric and Nervous Drugs Product and Services
2.9.4 Allergan Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 GSK
2.10.1 GSK Details
2.10.2 GSK Major Business
2.10.3 GSK Psychiatric and Nervous Drugs Product and Services
2.10.4 GSK Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Otsuka Pharmaceutical
2.11.1 Otsuka Pharmaceutical Details
2.11.2 Otsuka Pharmaceutical Major Business
2.11.3 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Product and Services
2.11.4 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Takeda
2.12.1 Takeda Details
2.12.2 Takeda Major Business
2.12.3 Takeda Psychiatric and Nervous Drugs Product and Services
2.12.4 Takeda Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 NHU Group
2.13.1 NHU Group Details
2.13.2 NHU Group Major Business
2.13.3 NHU Group Psychiatric and Nervous Drugs Product and Services
2.13.4 NHU Group Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Shionogi
2.14.1 Shionogi Details
2.14.2 Shionogi Major Business
2.14.3 Shionogi Psychiatric and Nervous Drugs Product and Services
2.14.4 Shionogi Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 APOTEX
2.15.1 APOTEX Details
2.15.2 APOTEX Major Business
2.15.3 APOTEX Psychiatric and Nervous Drugs Product and Services
2.15.4 APOTEX Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 Chengdu Kanghong Pharmaceutical
2.16.1 Chengdu Kanghong Pharmaceutical Details
2.16.2 Chengdu Kanghong Pharmaceutical Major Business
2.16.3 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Product and Services
2.16.4 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17 HUAHAI
2.17.1 HUAHAI Details
2.17.2 HUAHAI Major Business
2.17.3 HUAHAI Psychiatric and Nervous Drugs Product and Services
2.17.4 HUAHAI Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18 Zhejiang Jianfeng
2.18.1 Zhejiang Jianfeng Details
2.18.2 Zhejiang Jianfeng Major Business
2.18.3 Zhejiang Jianfeng Psychiatric and Nervous Drugs Product and Services
2.18.4 Zhejiang Jianfeng Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19 Beijing Winsunny Pharmaceutical
2.19.1 Beijing Winsunny Pharmaceutical Details
2.19.2 Beijing Winsunny Pharmaceutical Major Business
2.19.3 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Product and Services
2.19.4 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Psychiatric and Nervous Drugs Breakdown Data by Manufacturer
3.1 Global Psychiatric and Nervous Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Psychiatric and Nervous Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Psychiatric and Nervous Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Psychiatric and Nervous Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Psychiatric and Nervous Drugs Manufacturer Market Share in 2021
3.5 Global Psychiatric and Nervous Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Psychiatric and Nervous Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Psychiatric and Nervous Drugs Market Size by Region
4.1.1 Global Psychiatric and Nervous Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Psychiatric and Nervous Drugs Revenue by Region (2017-2028)
4.2 North America Psychiatric and Nervous Drugs Revenue (2017-2028)
4.3 Europe Psychiatric and Nervous Drugs Revenue (2017-2028)
4.4 Asia-Pacific Psychiatric and Nervous Drugs Revenue (2017-2028)
4.5 South America Psychiatric and Nervous Drugs Revenue (2017-2028)
4.6 Middle East and Africa Psychiatric and Nervous Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Psychiatric and Nervous Drugs Sales in Volume by Type (2017-2028)
5.2 Global Psychiatric and Nervous Drugs Revenue by Type (2017-2028)
5.3 Global Psychiatric and Nervous Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Psychiatric and Nervous Drugs Sales in Volume by Application (2017-2028)
6.2 Global Psychiatric and Nervous Drugs Revenue by Application (2017-2028)
6.3 Global Psychiatric and Nervous Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Psychiatric and Nervous Drugs Sales by Type (2017-2028)
7.2 North America Psychiatric and Nervous Drugs Sales by Application (2017-2028)
7.3 North America Psychiatric and Nervous Drugs Market Size by Country
7.3.1 North America Psychiatric and Nervous Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Psychiatric and Nervous Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Psychiatric and Nervous Drugs Sales by Type (2017-2028)
8.2 Europe Psychiatric and Nervous Drugs Sales by Application (2017-2028)
8.3 Europe Psychiatric and Nervous Drugs Market Size by Country
8.3.1 Europe Psychiatric and Nervous Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Psychiatric and Nervous Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Psychiatric and Nervous Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Psychiatric and Nervous Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Psychiatric and Nervous Drugs Market Size by Region
9.3.1 Asia-Pacific Psychiatric and Nervous Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Psychiatric and Nervous Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Psychiatric and Nervous Drugs Sales by Type (2017-2028)
10.2 South America Psychiatric and Nervous Drugs Sales by Application (2017-2028)
10.3 South America Psychiatric and Nervous Drugs Market Size by Country
10.3.1 South America Psychiatric and Nervous Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Psychiatric and Nervous Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Psychiatric and Nervous Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Psychiatric and Nervous Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Psychiatric and Nervous Drugs Market Size by Country
11.3.1 Middle East & Africa Psychiatric and Nervous Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Psychiatric and Nervous Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Psychiatric and Nervous Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Psychiatric and Nervous Drugs
12.3 Psychiatric and Nervous Drugs Production Process
12.4 Psychiatric and Nervous Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Psychiatric and Nervous Drugs Typical Distributors
13.3 Psychiatric and Nervous Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 精神薬＆神経薬の世界市場2022：抗うつ薬、抗不安薬、抗精神病薬、気分安定薬、覚醒剤、その他(Global Psychiatric and Nervous Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

精神薬＆神経薬の世界市場2022：抗うつ薬、抗不安薬、抗精神病薬、気分安定薬、覚醒剤、その他

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp